Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5531-5531 ◽

Author(s):

C. Le Tourneau ◽

E. Winquist ◽

S. J. Hotte ◽

S. A. Laurie ◽

D. Soulieres ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5567 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5567-5567 ◽

Author(s):

J. Guigay ◽

J. Fayette ◽

A. Dillies ◽

C. Sire ◽

J. N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Results ◽

First Line Treatment

Download Full-text

926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1336 ◽

2021 ◽

Vol 32 ◽

pp. S814

Author(s):

G. Obara ◽

J. Sun ◽

D. Loo ◽

C. Bohac

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5561 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5561-5561 ◽

Author(s):

L. L. Siu ◽

S. J. Hotte ◽

S. A. Laurie ◽

S. Singh ◽

E. Winquist ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Egf Receptor ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable, recurrent head and neck squamous cell carcinoma

Annals of Oncology ◽

10.1016/j.annonc.2020.08.1087 ◽

2020 ◽

Vol 31 ◽

pp. S683

Author(s):

K.J. Harrington ◽

W.N. William ◽

A. Khilnani ◽

A.P. Algazi

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Recurrent Head ◽

First Line Treatment

Download Full-text

Randomized Phase II Trial of Capecitabine Plus Cisplatin Versus Paclitaxel as First Line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Annals of Oncology ◽

10.1093/annonc/mdt203.59 ◽

2013 ◽

Vol 24 ◽

pp. iv53

Author(s):

Su Jin Lee ◽

Silvia Park ◽

Wonjin Chang ◽

Jung Yong Hong ◽

Moon Ki Choi ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.791652823 ◽

2012 ◽

Author(s):

Marco Merlano

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13355993.14726100 ◽

2011 ◽

Author(s):

Jan Vermorken

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)

Annals of Oncology ◽

10.1093/annonc/mdz449.043 ◽

2019 ◽

Vol 30 ◽

pp. xi32

Author(s):

J. Fayette

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Line Treatment ◽

Standard Chemotherapy ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

Annals of Oncology ◽

10.1093/annonc/mdy040 ◽

2018 ◽

Vol 29 (4) ◽

pp. 1004-1009 ◽

Author(s):

M. Tahara ◽

N. Kiyota ◽

T. Yokota ◽

Y. Hasegawa ◽

K. Muro ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Combination Treatment ◽

Phase Ii Trial ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text